The Florida Department of Health anticipates issuing a Funding Opportunity Announcement (FOA) by the end of June 2017 for the James and Esther King Biomedical Research Program.

For this FOA, the Department is interested in funding research proposals in the following research priorities:

- **Prevention and Treatment:** Research with a focus on prevention and improved treatment or care delivery that contributes to reductions in deaths due to lung cancer, breast cancer, prostate cancer, colon cancer, melanoma, or other tobacco-related diseases.
- **Health Disparities:** Research that contributes to reductions in deaths due to lung cancer, breast cancer, prostate cancer, colon cancer, and melanoma, or other tobacco-related diseases resulting from health disparities due to race, ethnicity, or income.
- **Screening:** Improve screening accuracy, detection of high risk subgroups, and/or improved implementation of a cancer screening program that results in an increase in early detection of cancer or preventable cancer. Alternatively, improve screening accuracy, detection, or implementation of a screening program for any disease related to tobacco use.
- **Tobacco Use:** Reduction of tobacco use in children, adolescents, and adults.
- **Obesity:** Enhance the understanding of the relationship between obesity, healthy weight, tobacco use, and cancer.
- **Treatment-Related Morbidities:** Expand upon research that improves scientific understanding of causes and subsequent impact of: cancer/cancer-treatment related morbidities in other systems (e.g., cardiovascular, pulmonary, endocrine, lymphatic, Central Nervous System, reproductive, developmental) or morbidity from diseases resulting from tobacco use.
- **Technology Transfer Feasibility (TFF):** The goals of the TTF grant mechanism are to: stimulate technology transfer activities for promising research discoveries that could lead to innovations in the prevention, diagnosis, treatment, and/or cure of tobacco-related diseases; and strengthen a project’s economic feasibility and commercialization prospects.
- **Investigational New Drug (IND) or Investigational Device Exemption (IDE):** This funding mechanism supports the development of Investigational New Drug and Investigational Device Exemption applications to the United States Food and Drug Administration as part of an application for marketing.

The following types of grants are available to pursue the research priorities:

<table>
<thead>
<tr>
<th>Grant Mechanism</th>
<th>Max Amount (including direct and indirect costs)</th>
<th>Max Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discovery Science</td>
<td>$900,000</td>
<td>3 years</td>
</tr>
<tr>
<td>Research Infrastructure</td>
<td>$1,500,000</td>
<td>3 years</td>
</tr>
<tr>
<td>Clinical Research</td>
<td>$1,500,000</td>
<td>5 years</td>
</tr>
<tr>
<td>Bridge</td>
<td>$100,000</td>
<td>6 months</td>
</tr>
</tbody>
</table>

Application details and deadlines will be listed in the Funding Opportunity Announcement.

All awards in response to this Funding Opportunity are subject to the availability of funds and spending authority provided by the Florida Legislature. Information is subject to change. Changes will be posted to the Program website. Applicants should monitor the website for changes and announcements.

Please click here to view the Program Website. To add your name to our mailing list, send an email with your contact information to research@flhealth.gov.